Introductions: We previously reported that autologous stem cell chem-mobilization with Etoposide +Cytarabine (EA) plus G-CSF was highly effective and safe for patients with multiple myeloma (MM). However, the state of mobilized CD34+ peripheral blood stem cells (PBSCs) and molecular mechanisms underlying its high-efficiency mobilization remain unknown.
Methods: Here, we employed matched single-cell transcriptome and chromatin accessibility sequencing to profile CD34+PBSCs of patients with MM(n=12) mobilized with EA+ G-CSF (n = 9), plerixafor + G-CSF (n = 3), along with healthy allo-donors (n = 5) mobilized with G-CSF. In addition, we integrated single-cell transcriptomic data with public CXCR4 inhibitors or G-CSF mobilized PBSC transcriptomic data to obtain a comprehensive map of seven mobilization strategies.
Results: The integrated map showed the alterations in the transcriptional landscape of mobilized PBSCs among mobilization strategies, revealing that EA plus G-CSF mobilized a higher fraction of hematopoietic stem cells (HSCs) and promoted a bias towards lymphoid differentiation compared to CXCR4 inhibitor and G-CSF. Meanwhile, CD34+ hematopoietic stem progenitor cells (HSPCs) mobilized by EA+G-CSF exhibited a higher proliferation capacity. We also explored the cellular and molecular basis of the high mobilization efficiency of CD34+ HSPCs by EA plus G-CSF in MM. Interestingly, we found that EA plus G-CSF mobilized CD34+ HSPCs exhibited significantly higher potential for cytarabine resistance, along with increased activity in the G-CSF signaling pathway and inflammatory response. The positive correlation between these three pathways suggested that chemotherapeutic agents may induce the endogenous G-CSF signaling pathway. Additionally, the JAK-STAT signaling pathway, which acts as a cross-talk mechanism between the G-CSF signaling pathway and the inflammatory response, also showed enhanced activity. Finally, we proposed the hypothesis of EA+G-CSF mobilization, suggesting that chemotherapeutic drug-induced changes in gene expression can either enhance (via the G-CSF pathway, RAC2, and ITGA4) or complement (via EGR1) the G-CSF mobilization process.
Conclusion: EA plus G-CSF mobilized a significantly higher fraction of CD34+ HSPCs favoring the lymphoid as well as proliferative capacity. EA-induced transcriptional changes might promote or complement G-CSF mobilization process to enhance PBSC mobilization efficacy in MM.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal